Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 204.6% during the third quarter, Holdings Channel.com reports. The fund owned 70,493 shares of the biotechnology company’s stock after purchasing an additional 47,353 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Sarepta Therapeutics were worth $1,358,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SRPT. Byrne Asset Management LLC acquired a new position in Sarepta Therapeutics during the third quarter worth $33,000. AlphaQuest LLC increased its stake in shares of Sarepta Therapeutics by 118.3% during the third quarter. AlphaQuest LLC now owns 2,561 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,388 shares in the last quarter. Covestor Ltd increased its stake in shares of Sarepta Therapeutics by 1,081.8% during the third quarter. Covestor Ltd now owns 2,789 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 2,553 shares in the last quarter. Blue Trust Inc. raised its position in shares of Sarepta Therapeutics by 542.3% during the 2nd quarter. Blue Trust Inc. now owns 3,282 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 2,771 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in Sarepta Therapeutics by 285.6% in the 3rd quarter. GAMMA Investing LLC now owns 3,089 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 2,288 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Buying and Selling

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total value of $294,201.97. Following the transaction, the chief operating officer directly owned 193,300 shares in the company, valued at $4,312,523. The trade was a 6.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 7.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on SRPT. Mizuho upgraded Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $19.00 to $26.00 in a research note on Wednesday, November 5th. Royal Bank Of Canada lifted their price target on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a research note on Thursday, January 8th. Wedbush boosted their price target on Sarepta Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Wells Fargo & Company dropped their target price on shares of Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. Nine analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $33.84.

Sarepta Therapeutics Trading Up 2.2%

Shares of SRPT stock opened at $17.79 on Friday. The company’s 50-day moving average price is $21.11 and its 200-day moving average price is $20.13. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -5.91, a PEG ratio of 0.44 and a beta of 0.39. Sarepta Therapeutics, Inc. has a twelve month low of $10.41 and a twelve month high of $111.21.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.